# OnCo record tempus-xt-cdx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tempus-xt-cdx/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tempus-xt-cdx" ;
  schema:name "Tempus xT CDx"@en ;
  schema:description "Tempus's tumour-and-normal gene panel, FDA-approved in 2023 as a companion test for EGFR antibodies in bowel cancer."@en ;
  schema:url <https://onco.cc/drugs/tempus-xt-cdx/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.tempus.com/oncology/genomic-profiling/xt-cdx/> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Tissue NGS companion diagnostic test (648 genes, tumour-normal)" ;
  schema:alternateName "xT CDx" ;
  onco:approval "US 2023: Companion diagnostic for cetuximab and panitumumab (KRAS/NRAS wild-type colorectal cancer) with tumour-profiling claims" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/> ;
  onco:companies <https://onco.cc/companies/tempus/> ;
  onco:terms <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/germline-vs-somatic/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/> .